Two Sigma Advisers LP Increases Stake in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Two Sigma Advisers LP raised its position in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 4.5% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 536,000 shares of the life sciences company's stock after buying an additional 23,300 shares during the period. Two Sigma Advisers LP owned about 0.69% of Integra LifeSciences worth $12,156,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Nisa Investment Advisors LLC lifted its position in shares of Integra LifeSciences by 599.6% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company's stock worth $74,000 after purchasing an additional 2,800 shares during the period. Choreo LLC increased its stake in shares of Integra LifeSciences by 29.9% in the 4th quarter. Choreo LLC now owns 22,274 shares of the life sciences company's stock worth $500,000 after acquiring an additional 5,123 shares in the last quarter. Empowered Funds LLC bought a new position in shares of Integra LifeSciences in the 4th quarter worth about $180,000. Principal Financial Group Inc. increased its stake in shares of Integra LifeSciences by 5.5% in the 4th quarter. Principal Financial Group Inc. now owns 423,432 shares of the life sciences company's stock worth $9,603,000 after acquiring an additional 22,000 shares in the last quarter. Finally, Leeward Investments LLC MA increased its stake in shares of Integra LifeSciences by 7.8% in the 4th quarter. Leeward Investments LLC MA now owns 405,506 shares of the life sciences company's stock worth $9,197,000 after acquiring an additional 29,402 shares in the last quarter. Hedge funds and other institutional investors own 84.78% of the company's stock.

Integra LifeSciences Stock Performance

Shares of IART traded down $0.15 on Wednesday, reaching $12.98. The company's stock had a trading volume of 107,960 shares, compared to its average volume of 861,531. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.20 and a quick ratio of 0.73. The stock has a market capitalization of $1.01 billion, a P/E ratio of -144.15, a PEG ratio of 0.73 and a beta of 1.27. The stock's 50 day simple moving average is $16.63 and its two-hundred day simple moving average is $21.17. Integra LifeSciences Holdings Co. has a 12-month low of $11.60 and a 12-month high of $32.66.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The life sciences company reported $0.41 earnings per share for the quarter, missing analysts' consensus estimates of $0.43 by ($0.02). The firm had revenue of $382.65 million during the quarter, compared to the consensus estimate of $381.17 million. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The business's revenue for the quarter was up 3.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.55 earnings per share. Research analysts forecast that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current fiscal year.

Analysts Set New Price Targets

IART has been the subject of several research reports. Argus upgraded shares of Integra LifeSciences from a "hold" rating to a "buy" rating in a research note on Monday, March 31st. Truist Financial decreased their price target on shares of Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating for the company in a research note on Friday, April 11th. Wells Fargo & Company decreased their price target on shares of Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating for the company in a research note on Tuesday, May 6th. JMP Securities reduced their price objective on shares of Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating for the company in a research note on Friday, May 9th. Finally, JPMorgan Chase & Co. reduced their price objective on shares of Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating for the company in a research note on Tuesday, May 6th. Four investment analysts have rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, Integra LifeSciences currently has an average rating of "Hold" and an average target price of $18.63.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.